Design, Synthesis, and Antifibrotic Evaluation of Silicon-Incorporated Alkyl Hydrazide Analogs of Tubastatin A: HDAC3 Selective Inhibitor for Ameliorating Liver Fibrosis
Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 25549-25574
DOI: 10.1021/acs.jmedchem.6c01449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.10.2026. Verfasst von Laxman D Nandawadekar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad500007, India. Hauptthemen laut MEDLINE: Liver Cirrhosis, Histone Deacetylase Inhibitors, Histone Deacetylases, Drug Design. Die Arbeit nennt 68 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, Council of Scientific and Industrial Research, India, Science and Engineering Research Board.
Abstract (Originalsprache)
Liver fibrosis remains a significant therapeutic challenge, with limited effective treatments and few clinically viable HDAC inhibitors despite their antifibrotic potential. Here, we report the design of silicon-incorporated alkyl hydrazide analogs of tubastatin-A to develop selective HDAC3 inhibitors via cap and zinc-binding motif optimization. These compounds were evaluated for HDAC-selectivity and antifibrotic activity in TGF-β-induced HSC-LX2 and HHSEC models, where 6b exhibited potent and selective HDAC3 inhibition (IC50-22 nM) with respect to HDAC5, HDAC6, HDAC8 along with robust antifibrotic activity, supported by molecular docking. ADMET studies indicated a favourable pharmacokinetic profile, permeability, microsomal stability, and a promising safety profile. Further validation in a CCl4-induced hepatic-fibrosis model, 6b demonstrated significant in-vivo efficacy by reducing AST/ALT levels, fibrotic marker expression and improving histopathology, outperforming tubastatin-A and nintedanib. Mechanistically, 6b significantly inhibited TGF-β/Smad signaling, likely through modulation of histone-acetylation patterns. Collectively, these findings identify 6b as a promising lead candidate for hepatic fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad500007, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad201002, India.
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad500007, India.
- Department of Natural Products & Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad500007, India.
ORCID-Profile: Sandip B Bharate, Sai Balaji Andugulapati, D Srinivasa Reddy
Förderung
- Department of Science and Technology, Ministry of Science and Technology
- Council of Scientific and Industrial Research, India
- Science and Engineering Research Board
- Council?of?Scientific and Industrial Research, India
Zitieren
APA
Nandawadekar, L. D., Sharma, N., Panneerselvam, S., Ramesh, E., Patekar, R. R., Routholla, G., Bharate, S. B., Andugulapati, S. B., & Reddy, D. S. (2026). Design, Synthesis, and Antifibrotic Evaluation of Silicon-Incorporated Alkyl Hydrazide Analogs of Tubastatin A: HDAC3 Selective Inhibitor for Ameliorating Liver Fibrosis. Journal of Medicinal Chemistry, 69(21), 25549-25574. https://doi.org/10.1021/acs.jmedchem.6c01449
Vancouver
Nandawadekar LD, Sharma N, Panneerselvam S, Ramesh E, Patekar RR, Routholla G, et al. Design, Synthesis, and Antifibrotic Evaluation of Silicon-Incorporated Alkyl Hydrazide Analogs of Tubastatin A: HDAC3 Selective Inhibitor for Ameliorating Liver Fibrosis. Journal of Medicinal Chemistry. 2026;69(21):25549-25574. doi:10.1021/acs.jmedchem.6c01449
BibTeX
@article{Nandawadekar2026,
author = {Nandawadekar, Laxman D and Sharma, Nidhi and Panneerselvam, Suriya and Ramesh, Eagala and Patekar, Rohan R and Routholla, Ganesh and Bharate, Sandip B and Andugulapati, Sai Balaji and Reddy, D Srinivasa},
title = {Design, Synthesis, and Antifibrotic Evaluation of Silicon-Incorporated Alkyl Hydrazide Analogs of Tubastatin A: HDAC3 Selective Inhibitor for Ameliorating Liver Fibrosis},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {21},
pages = {25549--25574},
doi = {10.1021/acs.jmedchem.6c01449}
}
EUVIMED